Title

HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC).

Authors

Harding, James J.; Macarulla, Teresa; Pant, Shubham; Wu, Xiaotian; Garfin, Phillip M.; Okusaka, Takuji

Publication

Journal of Clinical Oncology, 2025, Vol 43, pTPS648

ISSN

0732-183X

Publication type

Academic Journal

DOI

10.1200/JCO.2025.43.4_suppl.TPS648